There was initial confusion among front-line pharmacies regarding the return policy for Forxiga, which is set to be withdrawn from the Korean market. However, it appears that the issue is now being resolved.

According to the pharmacy industry sources, there has been a disagreement between AstraZeneca Korea and Daewoong Pharmaceutical regarding the return policy of Forxiga tablet following the decision for Forxiga withdrawal from the domestic market.

In 2018, AstraZeneca Korea entered into a partnership agreement with Daewoong Pharmaceutical to co-promote Forxiga and Xigduo. After the end of the domestic distribution contract with Daewoong Pharmaceutical, confusion arose in the ma